A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
← catalyst calendarNCT06433765 · readout in 3,146 d
Sponsored by TG Therapeutics, Inc. (industry) · TGTX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
728estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-01 | actual | When the study began enrolling |
| Primary completion | 2035-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2035-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis
Intervention
- Other: No intervention
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants with Major Congenital Malformations (MCMs)
measured Up to 52 weeks post-delivery
Permalink · TGTX's whole pipeline · Catalyst calendar · Every registered study · What changed